Orpro Therapeutics
OrPro Therapeutics is developing the Theradux® non-systemic biologic drug platform for treatment of diseases of the lung and other epithelial surfaces characterized by chronic infection, inflammation, and obstructive mucus. The company aims to address conditions such as cystic fibrosis and COVID-19-related lung issues through innovative biologic therapies, leveraging its proprietary platform and collaborations with leading research institutions.
Industries
Nr. of Employees
small (1-50)
Orpro Therapeutics
San Diego, California, United States
Patents
Products
Inhaled recombinant thioredoxin-derived biologic candidate (preclinical)
A recombinant thioredoxin-1-derived biologic formulated for inhalation to reduce airway inflammation and mucus obstruction, intended for treatment of chronic airway disorders (including cystic fibrosis) and to reduce progression to severe respiratory disease in viral infections.
ORP100S for Inhalation
An optimized aerosol formulation of a modified thioredoxin designed for direct delivery by inhalation to modulate pro-inflammatory cytokine release, reduce mucus viscosity, and restore mucociliary transport in conditions like cystic fibrosis.
Theradux
Non-systemic biologic drug platform developed for the treatment of diseases of the lung and other epithelial surfaces characterized by chronic infection, inflammation and obstructive mucus.
Inhaled recombinant thioredoxin-derived biologic candidate (preclinical)
A recombinant thioredoxin-1-derived biologic formulated for inhalation to reduce airway inflammation and mucus obstruction, intended for treatment of chronic airway disorders (including cystic fibrosis) and to reduce progression to severe respiratory disease in viral infections.
ORP100S for Inhalation
An optimized aerosol formulation of a modified thioredoxin designed for direct delivery by inhalation to modulate pro-inflammatory cytokine release, reduce mucus viscosity, and restore mucociliary transport in conditions like cystic fibrosis.
Theradux
Non-systemic biologic drug platform developed for the treatment of diseases of the lung and other epithelial surfaces characterized by chronic infection, inflammation and obstructive mucus.
Expertise Areas
- Inhaled biologics development
- Protein engineering and protein chemistry
- Mucosal immunology and mucus-normalizing therapeutics
- Preclinical respiratory disease models and efficacy testing
Key Technologies
- Recombinant protein biologics
- Aerosolized/inhalation delivery
- Protein disulfide reductase-based enzyme therapeutics
- Mucociliary transport assays
News & Updates
OrPro Therapeutics was recognized as a 2020 San Diego Cool Company, with industry veteran Ken Wilke joining the team to lead strategy and operations for the development of ORP100S.
In October 2016, OrPro Therapeutics and collaborators at the University of Alabama at Birmingham presented promising non-clinical data on the efficacy of Theradux™ during a poster session at the North American Cystic Fibrosis Conference.
In October 2015, U.S. Patent No. 9,168,290 was issued, covering the ability of Theradux™ (recombinant modified human thioredoxin-1).
In October 2014, OrPro Therapeutics presented data on its inhaled treatment for cystic fibrosis at the North American CF Conference.
In July 2012, OrPro Therapeutics received a Small Business Innovation Research (SBIR) grant from NIH to develop its lead product for cystic fibrosis.
Heifetz, P.B., Rancourt, R.C., and Nichols, D. (2014) Pediatric Pulmonology, 49(S38), 307
OrPro Therapeutics was recognized as a 2020 San Diego Cool Company, with industry veteran Ken Wilke joining the team to lead strategy and operations for the development of ORP100S.
In October 2016, OrPro Therapeutics and collaborators at the University of Alabama at Birmingham presented promising non-clinical data on the efficacy of Theradux™ during a poster session at the North American Cystic Fibrosis Conference.
In October 2015, U.S. Patent No. 9,168,290 was issued, covering the ability of Theradux™ (recombinant modified human thioredoxin-1).
In October 2014, OrPro Therapeutics presented data on its inhaled treatment for cystic fibrosis at the North American CF Conference.
In July 2012, OrPro Therapeutics received a Small Business Innovation Research (SBIR) grant from NIH to develop its lead product for cystic fibrosis.
Heifetz, P.B., Rancourt, R.C., and Nichols, D. (2014) Pediatric Pulmonology, 49(S38), 307